Seneca Therapeutics, Inc. (STI) was founded to develop the novel, clinically tested oncolytic Seneca Valley Virus (SVV) based on two key value drivers. First, oncolytic viruses (OV) have emerged as one of the most promising areas in cancer therapeutics today because oncolytic viruses elicit a potent immune response to cancer. Patient benefits include significant survival and response rate that in turn have led to FDA/EMA approvals, FDA breakthrough designations, and strong synergy with checkpoint inhibitors. As a result, Big Pharma has recently acquired several oncolytic virus companies, in some cases even before an agent has entered clinical trials. Second, over the past 18 months there has been a variety of groundbreaking and promising new information on Seneca Valley Virus making SVV uniquely selective toward solid cancer cells to the exclusion of normal cells and more bioavailable than other OVs. These and other newly discovered aspects make SVV best-in-class among oncolytic viruses.